ClinicalTrials.gg
Active, not recruitingNCT07046923Updated Nov 12, 2026

A Study of LY4175408 in Participants With Advanced Cancer

A Phase 1 interventional study of LY4175408 and Pembrolizumab in Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma and Endometrial Neoplasms, sponsored by Eli Lilly and Company. Active, not recruiting at 24 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Updated Nov 12, 2026Now Active, not recruitingNo longer in China+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
240
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company — 6 open to participants now, 20 under way, 6 of them phase 3. Carcinoma, Non-Small-Cell Lung · Eli Lilly and Company.

Planned enrollment
34th of 139
240 · median 109
Started
2025
with 1 other
Phase 1
28 of 147
3 open now
Primary completion
2030-07
later than 18 of 19 live
Registered
145th of 147
by date

Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 34th largest by planned enrollment of the 139 interventional ones that give a count, is one of 2 that started in 2025, is one of 28 in phase 1, reaches primary completion later than 18 of the 19 other live ones, and was the 145th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

6 of the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, or all of them as a file.
02

Study summary

The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could last up to 4 years.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
  • Small Cell Lung Carcinoma
  • Endometrial Neoplasms
  • Neoplasm Metastasis
  • Triple Negative Breast Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have one of the following advanced or solid tumor cancers:

    • Non-small cell lung cancer (NSCLC)
    • Small cell lung cancer (SCLC)
    • Endometrial cancer
    • Triple negative breast cancer (TNBC) (characterized by HR-negative disease and -negative expression according to American Society of Clinical Oncology (ASCO) - College of American Pathologists guidelines).
  • Received all standard therapies for which the individual was deemed to be an appropriate candidate by the treating investigator (except in Cohort B1 and B2 expansion, which require participants who are treatment naive in the advanced metastatic setting); OR the individual is refusing the remaining most appropriate standard of care treatment; OR there is no standard therapy available for the disease.
  • (ECOG) performance status of greater than or equal to (≤) 1.
  • For dose optimization/dose and expansion cohorts (Cohort A2, Cohort B/C): per (RECIST) v1.1.
  • Cohorts B1/B2: NSCLC with no known actionable genomic alterations. ≤2 for advanced or metastatic disease in safety lead-in; no prior systemic therapy in expansion

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with a protein tyrosine kinase 7 (PTK7) antibody-drug conjugate (ADC) with a topoisomerase I inhibitor as payload (prior therapy with a PTK7 ADC with a non-topoisomerase I inhibitor payload OR non-PTK7 ADC with any payload is permitted). Prior topoisomerase I-based ADCs are not allowed in cohorts A2, B1 or B2.
  • Any serious unresolved toxicities from prior therapy.
  • Individual with known or suspected history of uncontrolled central nervous system (CNS) .
  • Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection.
  • Significant cardiovascular disease.
  • Prolongation of corrected for heart rate using Fridericia's formula (QTcF) > 470 milliseconds (ms)
  • History of pneumonitis/interstitial lung disease.
  • Individuals who are pregnant, breastfeeding, or plan to breastfeed during the trial or within 30 days of the last dose of trial intervention.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Phase 1a Dose Escalation (Cohort A1)

    Escalating doses of LY4175408 administered intravenously (IV)

    Drug: LY4175408

  • Experimental
    Phase 1a Dose Optimization (Cohort A2)

    Two or more doses of LY4175408 (evaluated during dose escalation) administered IV

    Drug: LY4175408

  • Experimental
    Phase 1b Dose Expansion (Cohort B1)

    LY4175408 administered IV followed by pembrolizumab administered IV

    Drug: LY4175408 · Drug: Pembrolizumab

  • Experimental
    Phase 1b Dose Expansion (Cohort B2)

    LY4175408 administered IV followed by pembrolizumab administered IV and either carboplatin administered IV or cisplatin administered IV

    Drug: LY4175408 · Drug: Pembrolizumab · Drug: Carboplatin · Drug: Cisplatin

  • Experimental
    Phase 1b Dose Expansion (Cohorts C1, C2 and C3)

    LY4175408 administered IV

    Drug: LY4175408

Interventions

06

What researchers measure

Primary outcomes

  1. Phase 1a-Number of Participants with Dose Limiting Toxicities of LY4175408

    Time frame: 1 Cycle (21 days)

  2. Phase 1b-Overall Response Rate (ORR): Percentage of Participants with Best Response of Complete Response (CR) or Partial Response (PR)

    Per investigator assessed Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)

    Time frame: Baseline up to approximately 4 years

Secondary outcomes

  1. Phase 1a and 1b-Pharmacokinetics (PK): Minimum Plasma Concentration (Cmin) of LY4175408 (total antibody, conjugated antibody, free payload)

    Time frame: First 4 cycles (84 days)

  2. Phase 1a and 1b-PK: Area under the Concentration versus Time Curve (AUC) of LY4175408 (total antibody, conjugated antibody, free payload)

    Time frame: First 4 cycles (84 days)

  3. Phase 1a-ORR: Percentage of Participants with Best Response of CR or PR

    Per investigator assessed RECIST 1.1

    Time frame: Baseline up to approximately 4 years

  4. Phase 1a and 1b-Time to Response (TTR)

    Per investigator assessed RECIST 1.1

    Time frame: Baseline up to approximately 4 years

  5. Phase 1a and 1b-Progression-free Survival (PFS)

    Per investigator assessed RECIST 1.1

    Time frame: Baseline up to approximately 4 years

  6. Phase 1a and 1b-Disease Control Rate (DCR)

    Per investigator assessed RECIST 1.1

    Time frame: Baseline up to approximately 4 years

  7. Phase 1a and 1b-Duration of Response (DOR)

    Per investigator assessed RECIST 1.1

    Time frame: Baseline up to approximately 4 years

07

Study locations

24 sites
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jul 2030, 60 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 60 months is above that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2025
First posted
Jul 2, 2025
StartActual
Jul 28, 2025
Primary completionEst.
Jul 2030
CompletionEst.
Jul 2030
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 12, 2026
Sites
3 sites removed; no longer in China
Show 3 removed
  • West China Hospital, Sichuan University · Chengdu, China
  • Shanghai East Hospital, Tongji University · Shanghai, China
  • Tongji Hospital - Tongji Medical College of HUST · Wuhan, China
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Recruiting→Active, not recruiting
    3 sites removed; no longer in China
    Show 3 removed
    • West China Hospital, Sichuan University · Chengdu, China
    • Shanghai East Hospital, Tongji University · Shanghai, China
    • Tongji Hospital - Tongji Medical College of HUST · Wuhan, China
    + 3 other changes: identifiers, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07046923
Responsible party
Sponsor
First posted
Jul 2, 2025
Start date
Jul 28, 2025
Primary completion
Jul 2030 (estimated)
Completion
Jul 2030 (estimated)
Last update
Nov 12, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion